{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:43:04Z","timestamp":1792813384886,"version":"4.5.0"},"reference-count":212,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jacc.2025.07.052","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T14:29:57Z","timestamp":1758119397000},"page":"1917-1931","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Is Type 2 Diabetes a Modifiable Risk Factor for the Evolution and Progression of Heart Failure With a Preserved Ejection Fraction?"],"prefix":"10.1016","volume":"86","author":[{"given":"Milton","family":"Packer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.P.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry A.","family":"Borlaug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2025.07.052_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2337\/dci17-0052","article-title":"Heart failure: the most important, preventable, and treatable cardiovascular complication of type 2 diabetes","volume":"41","author":"Packer","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2025.07.052_bib2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(14)70219-0","article-title":"Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1\u00b79 million people","volume":"3","author":"Shah","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2025.07.052_bib3","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/ehf2.12782","article-title":"Diabetes mellitus and risk of new-onset and recurrent heart failure: a systematic review and meta-analysis","volume":"7","author":"Kodama","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacc.2025.07.052_bib4","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.2337\/dc10-0286","article-title":"Diabetes, glycemic control, and new-onset heart failure in patients with stable coronary artery disease: data from the Heart and Soul Study","volume":"33","author":"van Melle","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2025.07.052_bib5","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1161\/01.CIR.103.22.2668","article-title":"Glycemic control and heart failure among adult patients with diabetes","volume":"103","author":"Iribarren","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.07.052_bib6","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.amjcard.2017.03.005","article-title":"Comparison of predictors of heart failure with preserved versus reduced ejection fraction in a multiracial cohort of preclinical left ventricular diastolic dysfunction","volume":"119","author":"Zhang","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2025.07.052_bib7","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/ejhf.2894","volume":"25","author":"Anker","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.07.052_bib8","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/ejhf.1671","article-title":"Endothelium-dependent and independent coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction","volume":"22","author":"Yang","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.07.052_bib9","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1210\/jc.2017-01922","article-title":"Diabetic microvascular disease: an Endocrine Society Scientific Statement","volume":"102","author":"Barrett","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2025.07.052_bib10","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/cvr\/cvq102","article-title":"Hyperglycaemia-induced cardiomyocyte death is mediated via MCP-1 production and induction of a novel zinc-finger protein MCPIP","volume":"87","author":"Younce","year":"2010","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2025.07.052_bib11","doi-asserted-by":"crossref","first-page":"H1133","DOI":"10.1152\/ajpheart.00402.2010","article-title":"Adaptive induction of NF-E2-related factor-2-driven antioxidant genes in endothelial cells in response to hyperglycemia","volume":"300","author":"Ungvari","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jacc.2025.07.052_bib12","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/829758","article-title":"Ca+2\/calmodulin-dependent protein kinase mediates glucose toxicity-induced cardiomyocyte contractile dysfunction","volume":"2012","author":"Zhang","year":"2012","journal-title":"Exp Diabetes Res"},{"key":"10.1016\/j.jacc.2025.07.052_bib13","doi-asserted-by":"crossref","first-page":"C643","DOI":"10.1152\/ajpcell.00137.2010","article-title":"Cardiac contractile dysfunction during acute hyperglycemia due to impairment of SERCA by polyol pathway-mediated oxidative stress","volume":"299","author":"Tang","year":"2010","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.jacc.2025.07.052_bib14","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.2337\/diabetes.50.10.2363","article-title":"Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death","volume":"50","author":"Fiordaliso","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.jacc.2025.07.052_bib15","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.2337\/db16-1099","article-title":"Hyperglycemia-induced changes in ZIP7 and ZnT7 expression cause Zn(2+) release from the sarco(endo)plasmic reticulum and mediate ER stress in the heart","volume":"66","author":"Tuncay","year":"2017","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.jacc.2025.07.052_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163158","article-title":"Cardiac mitochondrial respiratory dysfunction and tissue damage in chronic hyperglycemia correlate with reduced aldehyde dehydrogenase-2 activity","volume":"11","author":"Mali","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2025.07.052_bib17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.freeradbiomed.2015.03.007","article-title":"Adiponectin ameliorates hyperglycemia-induced cardiac hypertrophy and dysfunction by concomitantly activating Nrf2 and Brg1","volume":"84","author":"Li","year":"2015","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.jacc.2025.07.052_bib18","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.cmet.2025.04.001","article-title":"Protein O-GlcNAcylation and hexokinase mitochondrial dissociation drive heart failure with preserved ejection fraction","volume":"37","author":"Tatekoshi","year":"2025","journal-title":"Cell Metab"},{"issue":"19","key":"10.1016\/j.jacc.2025.07.052_bib19","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.029898","article-title":"Sustained Increases in cardiomyocyte protein O-Linked \u03b2-N-Acetylglucosamine levels lead to cardiac hypertrophy and reduced mitochondrial function without systolic contractile impairment","volume":"12","author":"Ha","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.07.052_bib20","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.120.051911","article-title":"Excessive O-GlcNAcylation causes heart failure and sudden death","volume":"143","author":"Umapathi","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.07.052_bib21","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/cvr\/cvab043","article-title":"Fine-tuning the cardiac O-GlcNAcylation regulatory enzymes governs the functional and structural phenotype of the diabetic heart","volume":"118","author":"Prakoso","year":"2022","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2025.07.052_bib22","doi-asserted-by":"crossref","first-page":"26515","DOI":"10.1074\/jbc.M116.754481","article-title":"O-GlcNAcylation of 8-oxoguanine DNA glycosylase (Ogg1) impairs oxidative mitochondrial DNA lesion repair in diabetic hearts","volume":"29","author":"Cividini","year":"2016","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.jacc.2025.07.052_bib23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12933-023-01811-w","article-title":"Aldose reductase inhibition alleviates diabetic cardiomyopathy and is associated with a decrease in myocardial fatty acid oxidation","volume":"22","author":"Gopal","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2025.07.052_bib24","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1042\/CS20170063","article-title":"Phosphoinositide 3-kinase (p110alpha) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction","volume":"131","author":"Prakoso","year":"2017","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.jacc.2025.07.052_bib25","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3389\/fphys.2012.00292","article-title":"Advanced glycation end product cross-link breaker attenuates diabetes-induced cardiac dysfunction by improving sarcoplasmic reticulum calcium handling","volume":"3","author":"Kranstuber","year":"2012","journal-title":"Front Physiol"},{"key":"10.1016\/j.jacc.2025.07.052_bib26","doi-asserted-by":"crossref","first-page":"H2587","DOI":"10.1152\/ajpheart.00516.2003","article-title":"Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart","volume":"285","author":"Liu","year":"2003","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jacc.2025.07.052_bib27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jacc.2024.03.380","article-title":"Randomized trial of a selective aldose reductase inhibitor in patients with diabetic cardiomyopathy","volume":"84","author":"Januzzi","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.07.052_bib28","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/eurjhf\/hfr067","article-title":"Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure","volume":"13","author":"Hartog","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.07.052_bib29","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11695-010-0335-4","article-title":"Relationship between obesity and diabetes in a US adult population: findings from the National Health and Nutrition Examination Survey, 1999\u20132006","volume":"21","author":"Nguyen","year":"2010","journal-title":"Obes Surg"},{"issue":"1","key":"10.1016\/j.jacc.2025.07.052_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-22848-z","article-title":"Comparison of adiposity anthropometric indices and their associations with visceral fat levels determined by bioelectrical impedance analysis among diabetic patients","volume":"12","author":"Tuglo","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacc.2025.07.052_bib31","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.1111\/dom.16492","article-title":"The association between the visceral obesity indices and the future diabetes mellitus risk: A prospective cohort study","volume":"27","author":"Zhang","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.jacc.2025.07.052_bib32","article-title":"Waist-to-hip ratio better reflect beta-cell function and predicts diabetes risk in adult with overweight or obesity","volume":"57","author":"Liu","year":"2025","journal-title":"Ann Med"},{"issue":"6","key":"10.1016\/j.jacc.2025.07.052_bib33","doi-asserted-by":"crossref","DOI":"10.1177\/03000605251348229","article-title":"Association between long-term changes in obesity-related anthropometric indicators and the risk of type 2 diabetes mellitus in the older population","volume":"53","author":"Xu","year":"2025","journal-title":"J Int Med Res"},{"key":"10.1016\/j.jacc.2025.07.052_bib34","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/j.numecd.2024.06.019","article-title":"Longitudinal associations of DXA-measured visceral adipose tissue and cardiometabolic risk in middle-to-older aged adults","volume":"34","author":"Zhu","year":"2024","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.jacc.2025.07.052_bib35","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-019-0563-7","article-title":"Contribution of genetics to visceral adiposity and its relation to cardiovascular and metabolic disease","volume":"25","author":"Karlsson","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2025.07.052_bib36","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/2047487319851298","article-title":"Threshold body mass index and sex-specific waist circumference for increased risk of heart failure with preserved ejection fraction","volume":"26","author":"Campbell","year":"2019","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"10.1016\/j.jacc.2025.07.052_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2024-002711","article-title":"Adiposity, fat-free mass and incident heart failure in 500 000 individuals","volume":"11","author":"Oguntade","year":"2024","journal-title":"Open Heart"},{"key":"10.1016\/j.jacc.2025.07.052_bib38","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jchf.2018.05.018","article-title":"The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF","volume":"6","author":"Savji","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2025.07.052_bib39","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf057","article-title":"Near-universal prevalence of central adiposity and its prognostic significance in heart failure with mildly reduced or preserved ejection fraction: the PARAGON-HF trial","author":"Peikert","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.07.052_bib40","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jchf.2018.07.009","article-title":"Adiposity and incident heart failure and its subtypes: MESA (Multi-Ethnic Study of Atherosclerosis)","volume":"6","author":"Rao","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2025.07.052_bib41","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jacc.2024.10.111","article-title":"Finerenone, obesity, and heart failure with mildly reduced\/preserved ejection fraction: prespecified analysis of FINEARTS-HF","volume":"85","author":"Butt","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacc.2025.07.052_bib42","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s12872-021-02080-9","article-title":"Waist-to-height ratio is associated with an increased risk of mortality in Chinese patients with heart failure with preserved ejection fraction","volume":"21","author":"Chen","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jacc.2025.07.052_bib43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41401-023-01152-0","article-title":"Animal models of heart failure with preserved ejection fraction (HFpEF): from metabolic pathobiology to drug discovery","volume":"45","author":"Gao","year":"2024","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.jacc.2025.07.052_bib44","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jacbts.2021.12.009","article-title":"Clinical phenotypes of heart failure with preserved ejection fraction to select preclinical animal models","volume":"7","author":"van Ham","year":"2022","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jacc.2025.07.052_bib45","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1007\/s11695-023-06905-8","article-title":"Weight-loss independent clinical and metabolic biomarkers associated with type 2 diabetes remission post-bariatric\/metabolic surgery","volume":"33","author":"Chaiyasoot","year":"2023","journal-title":"Obes Surg"},{"key":"10.1016\/j.jacc.2025.07.052_bib46","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1007\/s11695-023-06741-w","article-title":"Sex-specific changes in body composition following metabolic and bariatric surgery are associated with the remission of metabolic syndrome","volume":"33","author":"Yi","year":"2023","journal-title":"Obes Surg"},{"issue":"8","key":"10.1016\/j.jacc.2025.07.052_bib47","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s11695-015-1973-3","article-title":"Is there a role for visceral adiposity in inducing type 2 diabetes remission in severely obese patients following biliopancreatic diversion with duodenal switch surgery?","volume":"26","author":"Auclair","year":"2016","journal-title":"Obes Surg"},{"key":"10.1016\/j.jacc.2025.07.052_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.soard.2021.09.009","article-title":"Bariatric surgery decreases the number of future hospital admissions for diastolic heart failure in subjects with severe obesity: a retrospective analysis of the US National Inpatient Sample database","volume":"18","author":"Romero Funes","year":"2022","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.jacc.2025.07.052_bib49","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.jacc.2022.08.738","article-title":"Long-term changes in cardiac structure and function following bariatric surgery","volume":"80","author":"Sorimachi","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.07.052_bib50","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1161\/CIRCULATIONAHA.121.055830","article-title":"Diabetes status modifies the association between different measures of obesity and heart failure risk among older adults: a pooled analysis of community-based NHLBI cohorts","volume":"145","author":"Patel","year":"2022","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jacc.2025.07.052_bib51","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/s12933-024-02418-5","article-title":"Adiposity modifies the association between heart failure risk and glucose metabolic disorder in older individuals: a community-based prospective cohort study","volume":"23","author":"Hou","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"16","key":"10.1016\/j.jacc.2025.07.052_bib52","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jacc.2025.06.055","article-title":"The adipokine hypothesis of heart failure with a preserved ejection fraction: a novel framework to explain pathogenesis and guide treatment","volume":"86","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.07.052_bib53","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1161\/CIRCULATIONAHA.117.032474","article-title":"Leptin-aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity","volume":"137","author":"Packer","year":"2018","journal-title":"Circulation"},{"issue":"41","key":"10.1016\/j.jacc.2025.07.052_bib54","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000031006","article-title":"Association of serum leptin and insulin levels among type 2 diabetes mellitus patients: a case-control study","volume":"101","author":"Zhao","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jacc.2025.07.052_bib55","first-page":"10515","article-title":"Hypoadiponectemia is associated with metabolic syndrome in patients with type 2 diabetes","volume":"10","author":"Wang","year":"2017","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.jacc.2025.07.052_bib56","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/0003319712440143","article-title":"Monocyte chemoattractant protein 1 is correlated with glycemic control and peripheral arterial disease in type 2 diabetic patients with metabolic syndrome","volume":"64","author":"Papatheodorou","year":"2013","journal-title":"Angiology"},{"key":"10.1016\/j.jacc.2025.07.052_bib57","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.2337\/diacare.27.6.1375","article-title":"Health, Aging, and Body Composition (ABC) Study. Adipocytokines attenuate the association between visceral adiposity and diabetes in older adults","volume":"27","author":"Kanaya","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2025.07.052_bib58","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/j.jacc.2018.03.509","article-title":"Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium","volume":"71","author":"Packer","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.07.052_bib59","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/ijo.2011.117","article-title":"Assessment of epicardial fat volume and myocardial triglyceride content in severely obese subjects: relationship to metabolic profile, cardiac function and visceral fat","volume":"36","author":"Gaborit","year":"2012","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.jacc.2025.07.052_bib60","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.07.052_bib61","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1463-1326.2004.00387.x","article-title":"High-fat diet enhances visceral advanced glycation end products, nuclear O-Glc-Nac modification, p38 mitogen-activated protein kinase activation and apoptosis","volume":"7","author":"Li","year":"2005","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2025.07.052_bib62","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1042\/BST20221066","article-title":"Insulin signalling and GLUT4 trafficking in insulin resistance","volume":"51","author":"van Gerwen","year":"2023","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.jacc.2025.07.052_bib63","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s00424-020-02417-x","article-title":"Glucose transporters in adipose tissue, liver, and skeletal muscle in metabolic health and disease","volume":"472","author":"Chadt","year":"2020","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.jacc.2025.07.052_bib64","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1172\/JCI115068","article-title":"Pretranslational suppression of a glucose transporter protein causes insulin resistance in adipocytes from patients with non-insulin-dependent diabetes mellitus and obesity","volume":"87","author":"Garvey","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacc.2025.07.052_bib65","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/35055575","article-title":"Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver","volume":"409","author":"Abel","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2025.07.052_bib66","doi-asserted-by":"crossref","first-page":"E551","DOI":"10.1152\/ajpendo.00116.2005","article-title":"Adipose-specific overexpression of GLUT4 reverses insulin resistance and diabetes in mice lacking GLUT4 selectively in muscle","volume":"289","author":"Carvalho","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.jacc.2025.07.052_bib67","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/s001250050720","article-title":"Regional variation in adipose tissue insulin action and GLUT4 glucose transporter expression in severely obese premenopausal women","volume":"40","author":"Marette","year":"1997","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacc.2025.07.052_bib68","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2337\/diab.46.1.3","article-title":"Role of fatty acids in the pathogenesis of insulin resistance and NIDDM","volume":"46","author":"Boden","year":"1997","journal-title":"Diabetes"},{"issue":"24","key":"10.1016\/j.jacc.2025.07.052_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222413361","article-title":"Adipose lipolysis regulates cardiac glucose uptake and function in mice under cold stress","volume":"22","author":"Choi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacc.2025.07.052_bib70","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2119\/2008-00058.Rabe","article-title":"Adipokines and insulin resistance","volume":"14","author":"Rabe","year":"2008","journal-title":"Mol Med"},{"key":"10.1016\/j.jacc.2025.07.052_bib71","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s00125-004-1609-y","article-title":"Globular adiponectin increases GLUT4 translocation and glucose uptake but reduces glycogen synthesis in rat skeletal muscle cells","volume":"48","author":"Ceddia","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacc.2025.07.052_bib72","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature03711","article-title":"Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes","volume":"436","author":"Yang","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2025.07.052_bib73","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1096\/fj.201901979RR","article-title":"RBP4 increases lipolysis in human adipocytes and is associated with increased lipolysis and hepatic insulin resistance in obese women","volume":"34","author":"Kilicarslan","year":"2020","journal-title":"FASEB J"},{"key":"10.1016\/j.jacc.2025.07.052_bib74","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1172\/JCI200421341","article-title":"GLUT4 glucose transporter deficiency increases hepatic lipid production and peripheral lipid utilization","volume":"114","author":"Kotani","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacc.2025.07.052_bib75","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2337\/diab.41.2.187","article-title":"Glucose transporter levels in tissues of spontaneously diabetic Zucker fa\/fa rat (ZDF\/drt) and viable yellow mouse (Avy\/a)","volume":"41","author":"Slieker","year":"1992","journal-title":"Diabetes"},{"key":"10.1016\/j.jacc.2025.07.052_bib76","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0008-6363(95)00019-4","article-title":"Decreased GLUT-4 mRNA content and insulin-sensitive deoxyglucose uptake show insulin resistance in the hypertensive rat heart","volume":"30","author":"Paternostro","year":"1995","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2025.07.052_bib77","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s001250050946","article-title":"Insulin resistance characterizes glucose uptake in skeletal muscle but not in the heart in NIDDM","volume":"41","author":"Utriainen","year":"1998","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacc.2025.07.052_bib78","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1161\/01.CIR.103.13.1734","article-title":"Effect of non-insulin-dependent diabetes mellitus on myocardial insulin responsiveness in patients with ischemic heart disease","volume":"103","author":"Jagasia","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.07.052_bib79","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1016\/j.jacc.2006.06.078","article-title":"Myocardial glucose transport and utilization in patients with type 2 diabetes mellitus, left ventricular dysfunction, and coronary artery disease","volume":"48","author":"Dutka","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.07.052_bib80","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.2337\/db19-1057","article-title":"Maintaining myocardial glucose utilization in diabetic cardiomyopathy accelerates mitochondrial dysfunction","volume":"69","author":"Wende","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.jacc.2025.07.052_bib81","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/oby.2011.208","article-title":"Sex and type 2 diabetes: obesity-independent effects on left ventricular substrate metabolism and relaxation in humans","volume":"20","author":"Peterson","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jacc.2025.07.052_bib82","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/13813450701783281","article-title":"Rosiglitazone treatment improves cardiac efficiency in hearts from diabetic mice","volume":"113","author":"How","year":"2007","journal-title":"Arch Physiol Biochem"},{"key":"10.1016\/j.jacc.2025.07.052_bib83","doi-asserted-by":"crossref","first-page":"R1202","DOI":"10.1152\/ajpregu.90820.2008","article-title":"Cardiac and skeletal muscle fatty acid transport and transporters and triacylglycerol and fatty acid oxidation in lean and Zucker diabetic fatty rats","volume":"297","author":"Bonen","year":"2009","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.jacc.2025.07.052_bib84","doi-asserted-by":"crossref","first-page":"40567","DOI":"10.1074\/jbc.M100052200","article-title":"Increased rates of fatty acid uptake and plasmalemmal fatty acid transporters in obese Zucker rats","volume":"276","author":"Luiken","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacc.2025.07.052_bib85","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/13813450701422617","article-title":"Mechanisms responsible for enhanced fatty acid utilization by perfused hearts from type 2 diabetic db\/db mice","volume":"113","author":"Carley","year":"2007","journal-title":"Arch Physiol Biochem"},{"key":"10.1016\/j.jacc.2025.07.052_bib86","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1113\/jphysiol.2010.198663","article-title":"In obese Zucker rats, lipids accumulate in the heart despite normal mitochondrial content, morphology and long-chain fatty acid oxidation","volume":"589","author":"Holloway","year":"2011","journal-title":"J Physiol"},{"key":"10.1016\/j.jacc.2025.07.052_bib87","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.2337\/db09-1293","article-title":"Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption","volume":"59","author":"Ussher","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.jacc.2025.07.052_bib88","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/cvr\/cvq266","article-title":"Cardiac diacylglycerol accumulation in high fat-fed mice is associated with impaired insulin-stimulated glucose oxidation","volume":"89","author":"Zhang","year":"2011","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2025.07.052_bib89","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.yjmcc.2025.02.010","article-title":"Lipotoxicity as a therapeutic target in the type 2 diabetic heart","volume":"201","author":"Luong","year":"2025","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.jacc.2025.07.052_bib90","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1161\/CIRCULATIONAHA.106.645614","article-title":"Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study","volume":"116","author":"McGavock","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.07.052_bib91","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/07435800.2013.879165","article-title":"Adiponectin receptor 1 overexpression reduces lipid accumulation and hypertrophy in the heart of diet-induced obese mice--possible involvement of oxidative stress and autophagy","volume":"39","author":"Chou","year":"2014","journal-title":"Endocr Res"},{"key":"10.1016\/j.jacc.2025.07.052_bib92","article-title":"CTRP3 attenuates myocardial lipotoxicity via suppression of lipid accumulation, inflammation, apoptosis, and mitochondrial oxidative stress","volume":"12","author":"Wang","year":"2025","journal-title":"Front Cardiovasc Med"},{"issue":"6","key":"10.1016\/j.jacc.2025.07.052_bib93","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000433","article-title":"Taking diabetes to heart\u2014deregulation of myocardial lipid metabolism in diabetic cardiomyopathy","volume":"2","author":"Bayeva","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.07.052_bib94","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41569-022-00824-4","article-title":"SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism","volume":"20","author":"Packer","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"10.1016\/j.jacc.2025.07.052_bib95","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12933-020-01044-1","article-title":"Metabolic syndrome and myocardium steatosis in subclinical type 2 diabetes mellitus: a (1)H-magnetic resonance spectroscopy study","volume":"19","author":"Gao","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2025.07.052_bib96","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.metabol.2016.05.006","article-title":"Effects of lifestyle intervention on left ventricular regional myocardial function in metabolic syndrome patients from the RESOLVE randomized trial","volume":"65","author":"Serrano-Ferrer","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.jacc.2025.07.052_bib97","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1194\/jlr.P900032-JLR200","article-title":"Myocardial lipid accumulation in patients with pressure-overloaded heart and metabolic syndrome","volume":"50","author":"Marfella","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacc.2025.07.052_bib98","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1096\/fj.04-2263com","article-title":"Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart","volume":"18","author":"Sharma","year":"2004","journal-title":"FASEB J"},{"issue":"1","key":"10.1016\/j.jacc.2025.07.052_bib99","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1532-429X-15-103","article-title":"Cardiac steatosis and left ventricular function in men with metabolic syndrome","volume":"15","author":"Nyman","year":"2013","journal-title":"J Cardiovasc Magn Reson"},{"issue":"9","key":"10.1016\/j.jacc.2025.07.052_bib100","first-page":"1699","article-title":"The impact of obesity on cardiac energy metabolism and efficiency in heart failure with preserved ejection fraction","volume":"41","author":"Ketema","year":"2025","journal-title":"Can J Cardiol"},{"issue":"12","key":"10.1016\/j.jacc.2025.07.052_bib101","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050077","article-title":"Effects of insulin therapy on myocardial lipid content and cardiac geometry in patients with type-2 diabetes mellitus","volume":"7","author":"Jankovic","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2025.07.052_bib102","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1479164111428628","article-title":"The effects of rosiglitazone on myocardial triglyceride content in patients with type 2 diabetes: a randomised, placebo-controlled trial","volume":"9","author":"McGavock","year":"2012","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.jacc.2025.07.052_bib103","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/jmri.22879","article-title":"Left ventricular diastolic function in type 2 diabetes mellitus is associated with myocardial triglyceride content but not with impaired myocardial perfusion reserve","volume":"35","author":"Korosoglou","year":"2012","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.jacc.2025.07.052_bib104","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/ejhf.1617","article-title":"Myocardial adipose deposition and the development of heart failure with preserved ejection fraction","volume":"22","author":"Wu","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.07.052_bib105","doi-asserted-by":"crossref","DOI":"10.1038\/srep18495","article-title":"Associations of different adipose tissue depots with insulin resistance: a systematic review and meta-analysis of observational studies","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacc.2025.07.052_bib106","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1172\/JCI119628","article-title":"Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR)","volume":"100","author":"Ferrannini","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacc.2025.07.052_bib107","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1210\/jcem-59-6-1121","article-title":"Peripheral hyperinsulinemia of simple obesity: pancreatic hypersecretion or impaired insulin metabolism?","volume":"59","author":"Bonora","year":"1984","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.jacc.2025.07.052_bib108","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3390\/ijms20030759","article-title":"Insulin and insulin receptors in adipose tissue development","volume":"20","author":"Cignarelli","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacc.2025.07.052_bib109","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jacbts.2018.04.003","article-title":"Potentiation of insulin signaling contributes to heart failure in type 2 diabetes: a hypothesis supported by both mechanistic studies and clinical trials","volume":"3","author":"Packer","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jacc.2025.07.052_bib110","doi-asserted-by":"crossref","first-page":"R1101","DOI":"10.1152\/ajpregu.00390.2012","article-title":"Sodium-retaining effect of insulin in diabetes","volume":"303","author":"Brands","year":"2012","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.jacc.2025.07.052_bib111","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1161\/CIRCULATIONAHA.117.030924","article-title":"Effect of basal insulin glargine on first and recurrent episodes of heart failure hospitalization: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)","volume":"137","author":"Gerstein","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.07.052_bib112","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.jacc.2025.03.530","article-title":"Disentangling the impact of adiposity from insulin resistance in heart failure with preserved ejection fraction","volume":"85","author":"Reddy","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.07.052_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.cardfail.2009.03.001","article-title":"Glycemic status and incident heart failure in elderly without history of diabetes mellitus: the Health, Aging, and Body Composition study","volume":"15","author":"Kalogeropoulos","year":"2009","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2025.07.052_bib114","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.cardfail.2022.01.011","article-title":"Glycemic markers and heart failure subtypes: the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"28","author":"Echouffo-Tcheugui","year":"2022","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2025.07.052_bib115","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.2337\/diabetes.54.8.2447","article-title":"Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals","volume":"54","author":"Kim","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.jacc.2025.07.052_bib116","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1172\/JCI30335","article-title":"Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice","volume":"117","author":"Son","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacc.2025.07.052_bib117","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.toxlet.2017.08.011","article-title":"Rosiglitazone promotes cardiac hypertrophy and alters chromatin remodeling in isolated cardiomyocytes","volume":"280","author":"Pharaon","year":"2017","journal-title":"Toxicol Lett"},{"issue":"16","key":"10.1016\/j.jacc.2025.07.052_bib118","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89908","article-title":"Adipocyte-specific loss of PPARgamma attenuates cardiac hypertrophy","volume":"1","author":"Fang","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jacc.2025.07.052_bib119","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/1074248411423022","article-title":"Effects of pioglitazone on high-fat-diet-induced ventricular remodeling and dysfunction in rats","volume":"17","author":"Tian","year":"2012","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.jacc.2025.07.052_bib120","first-page":"4597","article-title":"PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance","author":"Kubota","year":"1999","journal-title":"Mol Cell"},{"key":"10.1016\/j.jacc.2025.07.052_bib121","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1111\/dom.15526","article-title":"A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin","volume":"26","author":"Lim","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2025.07.052_bib122","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/01.RES.0000179226.34112.6d","article-title":"Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice","volume":"97","author":"Duan","year":"2005","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.jacc.2025.07.052_bib123","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12933-021-01242-5","article-title":"Diabetic phenotype and prognosis of patients with heart failure and preserved ejection fraction in a real life cohort","volume":"20","author":"Lejeune","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.jacc.2025.07.052_bib124","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12933-021-01379-3","article-title":"Effect of diabetes mellitus on the development of left ventricular contractile dysfunction in women with heart failure and preserved ejection fraction","volume":"20","author":"Shi","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2025.07.052_bib125","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.883615","article-title":"Diabetes is the strongest predictor of limited exercise capacity in chronic heart failure and preserved ejection fraction (HFpEF)","volume":"9","author":"Berisha-Muharremi","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacc.2025.07.052_bib126","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jacc.2014.05.030","article-title":"Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study","volume":"64","author":"Lindman","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.07.052_bib127","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/ejhf.2403","article-title":"Diabetes and pre-diabetes in patients with heart failure and preserved ejection fraction","volume":"24","author":"Jackson","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.07.052_bib128","article-title":"AGE-RAGE axis and cardiovascular diseases: pathophysiologic mechanisms and prospects for clinical applications","author":"Wang","year":"2024","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacc.2025.07.052_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120860","article-title":"Aftermath of AGE-RAGE cascade in the pathophysiology of cardiovascular ailments","volume":"307","author":"Wasim","year":"2022","journal-title":"Life Sci"},{"issue":"8","key":"10.1016\/j.jacc.2025.07.052_bib130","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.3390\/ijms26083707","article-title":"The advanced glycation end-products (AGE)-receptor for AGE system (RAGE): an inflammatory pathway linking obesity and cardiovascular diseases","volume":"26","author":"Vianello","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacc.2025.07.052_bib131","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.bbrc.2016.06.056","article-title":"Age-related accumulation of advanced glycation end-products-albumin, S100\u03b2, and the expressions of advanced glycation end product receptor differ in visceral and subcutaneous fat","volume":"477","author":"Son","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jacc.2025.07.052_bib132","doi-asserted-by":"crossref","first-page":"478","DOI":"10.2337\/db11-1116","article-title":"Receptor for advanced glycation end products regulates adipocyte hypertrophy and insulin sensitivity in mice: involvement of Toll-like receptor 2","volume":"62","author":"Monden","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.jacc.2025.07.052_bib133","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/cvr\/cvac175","article-title":"The RAGE\/DIAPH1 axis: mediator of obesity and proposed biomarker of human cardiometabolic disease","volume":"119","author":"Arivazhagan","year":"2024","journal-title":"Cardiovasc Res"},{"issue":"1","key":"10.1016\/j.jacc.2025.07.052_bib134","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41420-021-00711-w","article-title":"Role of RAGE in obesity-induced adipose tissue inflammation and insulin resistance","volume":"7","author":"Feng","year":"2021","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.jacc.2025.07.052_bib135","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1002\/oby.23774","article-title":"Pharmacological antagonism of receptor for advanced glycation end products signaling promotes thermogenesis, healthful body mass and composition, and metabolism in mice","volume":"31","author":"Wilson","year":"2023","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jacc.2025.07.052_bib136","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1161\/ATVBAHA.113.302281","article-title":"N\u03b5-(carboxymethyl)lysine-receptor for advanced glycation end product axis is a key modulator of obesity-induced dysregulation of adipokine expression and insulin resistance","volume":"34","author":"Gaens","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.jacc.2025.07.052_bib137","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41420-023-01708-3","article-title":"Pathological roles of bone marrow adipocyte-derived monocyte chemotactic protein-1 in type 2 diabetic mice","volume":"9","author":"Wan","year":"2023","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.jacc.2025.07.052_bib138","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.diabres.2006.09.016","article-title":"Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes","volume":"76","author":"Unoki","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jacc.2025.07.052_bib139","doi-asserted-by":"crossref","first-page":"E323","DOI":"10.1152\/ajpendo.00024.2008","article-title":"Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs","volume":"295","author":"Tikellis","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.jacc.2025.07.052_bib140","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1006\/jmcc.2002.2084","article-title":"Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes","volume":"34","author":"Petrova","year":"2002","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.jacc.2025.07.052_bib141","doi-asserted-by":"crossref","first-page":"E539","DOI":"10.1152\/ajpendo.00450.2020","article-title":"Activation of RAGE-dependent endoplasmic reticulum stress associates with exacerbated postmyocardial infarction ventricular arrhythmias in diabetes","volume":"320","author":"Liu","year":"2021","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.jacc.2025.07.052_bib142","doi-asserted-by":"crossref","first-page":"H63","DOI":"10.1152\/ajpheart.00043.2015","article-title":"Cardiomyocyte mitochondrial respiration is reduced by receptor for advanced glycation end-product signaling in a ceramide-dependent manner","volume":"309","author":"Nelson","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jacc.2025.07.052_bib143","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1113\/EP090042","article-title":"AGEs-RAGE axis mediates myocardial fibrosis via activation of cardiac fibroblasts induced by autophagy in heart failure","volume":"107","author":"Liang","year":"2022","journal-title":"Exp Physiol"},{"issue":"1","key":"10.1016\/j.jacc.2025.07.052_bib144","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.84969","article-title":"Interaction of beta1-adrenoceptor with RAGE mediates cardiomyopathy via CaMKII signaling","volume":"1","author":"Zhu","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jacc.2025.07.052_bib145","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/2712376","article-title":"Soluble receptor for advanced glycation end products: a protective molecule against intramyocardial lipid accumulation in obese Zucker rats?","volume":"2019","author":"Dozio","year":"2019","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jacc.2025.07.052_bib146","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ejphar.2016.07.008","article-title":"Blockade of receptor for advanced glycation end products protects against systolic overload-induced heart failure after transverse aortic constriction in mice","volume":"791","author":"Liu","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jacc.2025.07.052_bib147","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/eurjhf\/hfq117","article-title":"Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels: New Roles for Soluble RAGE","volume":"12","author":"Raposeiras-Roub\u00edn","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.07.052_bib148","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cardfail.2007.10.019","article-title":"Soluble receptor for advanced glycation end products (RAGE) is a prognostic factor for heart failure","volume":"14","author":"Koyama","year":"2008","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2025.07.052_bib149","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3109\/14017431.2015.1039571","article-title":"New insights into the mechanisms of diastolic dysfunction in patients with type 2 diabetes","volume":"49","author":"Bayraktar","year":"2015","journal-title":"Scand Cardiovasc J"},{"key":"10.1016\/j.jacc.2025.07.052_bib150","doi-asserted-by":"crossref","first-page":"E631","DOI":"10.1152\/ajpendo.00146.2017","article-title":"Circulating soluble RAGE isoforms are attenuated in obese, impaired-glucose-tolerant individuals and are associated with the development of type 2 diabetes","volume":"313","author":"Miranda","year":"2017","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.jacc.2025.07.052_bib151","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.7150\/ijbs.56379","article-title":"Soluble receptor for advanced glycation end-products regulates age-associated cardiac fibrosis","volume":"17","author":"Scavello","year":"2021","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.jacc.2025.07.052_bib152","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.07.052_bib153","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/11587580-000000000-00000","article-title":"Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials","volume":"11","author":"Hernandez","year":"2011","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jacc.2025.07.052_bib154","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/clc.23844","article-title":"Re-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors","volume":"45","author":"Scirica","year":"2022","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacc.2025.07.052_bib155","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2025.07.052_bib156","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1007\/s00125-022-05773-8","article-title":"SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits","volume":"65","author":"Marilly","year":"2022","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.jacc.2025.07.052_bib157","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1210\/clinem\/dgad398","article-title":"Glucagon-like peptide-1 receptor agonists across the spectrum of heart failure","volume":"109","author":"Ferreira","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2025.07.052_bib158","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/ejhf.3478","article-title":"Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: the EXSCEL trial","volume":"27","author":"Neves","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.07.052_bib159","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.07.052_bib160","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.07.052_bib161","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jacc.2025.06.058","article-title":"Influence of type 2 diabetes on the effects of tirzepatide in patients with heart failure and a preserved ejection fraction with obesity: a prespecified stratification-based analysis","volume":"86","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.07.052_bib162","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2213-8587(24)00304-8","article-title":"Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA(1c) levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial","volume":"13","author":"Davies","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2025.07.052_bib163","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/CIRCULATIONAHA.122.059785","article-title":"Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes","volume":"146","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.07.052_bib164","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S2213-8587(22)00308-4","volume":"10","author":"Inzucchi","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2025.07.052_bib165","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/ejhf.3269","article-title":"Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose-lowering therapy: a pre-specified analysis of the DELIVER trial","volume":"26","author":"Lassen","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.07.052_bib166","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jacc.2025.04.059","article-title":"Impact of body mass index, central adiposity, and weight loss on the benefits of tirzepatide in HFpEF: the SUMMIT trial","volume":"86","author":"Borlaug","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.07.052_bib167","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/s41591-023-02526-x","article-title":"Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial","volume":"29","author":"Borlaug","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2025.07.052_bib168","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1093\/eurheartj\/ehac481","article-title":"Dapagliflozin for heart failure according to body mass index: the DELIVER trial","volume":"43","author":"Adamson","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.07.052_bib169","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/ejhf.2831","article-title":"Health status across major subgroups of patients with heart failure and preserved ejection fraction","volume":"25","author":"Siddiqi","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.07.052_bib170","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1161\/CIRCULATIONAHA.123.065134","article-title":"Cardiac and metabolic effects of dapagliflozin in heart failure with preserved ejection fraction: the CAMEO-DAPA trial","volume":"148","author":"Borlaug","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.07.052_bib171","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2337\/dci19-0074","article-title":"SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action","volume":"43","author":"Packer","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2025.07.052_bib172","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.07.052_bib173","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/cbf.3751","article-title":"Semaglutide (GLP-1 receptor agonist) stimulates browning on subcutaneous fat adipocytes and mitigates inflammation and endoplasmic reticulum stress in visceral fat adipocytes of obese mice","volume":"40","author":"Martins","year":"2022","journal-title":"Cell Biochem Funct"},{"key":"10.1016\/j.jacc.2025.07.052_bib174","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1007\/s00125-012-2592-3","article-title":"Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes","volume":"55","author":"Lee","year":"2012","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.jacc.2025.07.052_bib175","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1038\/s41467-020-18751-8","article-title":"Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism","volume":"11","author":"Killion","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacc.2025.07.052_bib176","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2024.100185","article-title":"Liraglutide improves adipose tissue remodeling and mitochondrial dynamics in a visceral obesity model induced by a high-fat diet","volume":"6","author":"Touceda","year":"2024","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"10.1016\/j.jacc.2025.07.052_bib177","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1080\/21623945.2020.1807850","article-title":"The diabetes medication canagliflozin promotes mitochondrial remodelling of adipocyte via the AMPK-Sirt1-Pgc-1alpha signalling pathway","volume":"9","author":"Yang","year":"2020","journal-title":"Adipocyte"},{"issue":"6","key":"10.1016\/j.jacc.2025.07.052_bib178","doi-asserted-by":"crossref","first-page":"921","DOI":"10.4093\/dmj.2020.0187","article-title":"Ipragliflozin, an SGLT2 inhibitor, ameliorates high-fat diet-induced metabolic changes by upregulating energy expenditure through activation of the AMPK\/ SIRT1 pathway","volume":"45","author":"Lee","year":"2021","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.jacc.2025.07.052_bib179","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117414","article-title":"Canagliflozin ameliorates obesity by improving mitochondrial function and fatty acid oxidation via PPARalpha in vivo and in vitro","volume":"247","author":"Wei","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.jacc.2025.07.052_bib180","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2024.112320","article-title":"SGLT2 inhibitor canagliflozin reduces visceral adipose tissue in db\/db mice by modulating AMPK\/KLF4 signaling and regulating mitochondrial dynamics to induce browning","volume":"592","author":"Qu","year":"2024","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.jacc.2025.07.052_bib181","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jacbts.2023.05.007","article-title":"Empagliflozin suppresses the differentiation\/maturation of human epicardial preadipocytes and improves paracrine secretome profile","volume":"8","author":"Takano","year":"2023","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jacc.2025.07.052_bib182","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"issue":"10","key":"10.1016\/j.jacc.2025.07.052_bib183","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e11012","article-title":"Beneficial effects of SGLT2 inhibitor on metabolic inflexibility and visceral fat amount in animal model of obese type 2 diabetes","volume":"8","author":"Hara","year":"2022","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.jacc.2025.07.052_bib184","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13098-023-01085-y","article-title":"Effects of SGLT-2 inhibitors on adipose tissue distribution in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Wang","year":"2023","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.jacc.2025.07.052_bib185","article-title":"The effects of sodium-glucose cotransporter 2 inhibitors on adipose tissue in patients with type 2 diabetes: A meta-analysis of randomized controlled trials","volume":"14","author":"Liu","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jacc.2025.07.052_bib186","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s13300-020-00949-0","article-title":"Comparison of visceral fat reduction by ipragliflozin and metformin in elderly type 2 diabetes patients: sub-analysis of a randomized-controlled study","volume":"12","author":"Koshizaka","year":"2021","journal-title":"Diabetes Ther"},{"issue":"1","key":"10.1016\/j.jacc.2025.07.052_bib187","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/s12933-023-02091-0","article-title":"Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes","volume":"22","author":"Cinti","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.jacc.2025.07.052_bib188","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","article-title":"The effect of dapagliflozin treatment on epicardial adipose tissue volume","volume":"17","author":"Sato","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2025.07.052_bib189","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/dom.16107","article-title":"SGLT2 inhibitors reduce epicardial adipose tissue more than GLP-1 agonists or exercise interventions in patients with type 2 diabetes mellitus and\/or obesity: a systematic review and network meta-analysis","volume":"27","author":"Bao","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2025.07.052_bib190","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.jacc.2025.07.052_bib191","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","article-title":"Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy","volume":"85","author":"Kramer","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacc.2025.07.052_bib192","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12933-021-01237-2","article-title":"Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study","volume":"20","author":"Gaborit","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2025.07.052_bib193","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/dom.12680","article-title":"Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy","volume":"18","author":"Dutour","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2025.07.052_bib194","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s42000-023-00493-z","article-title":"Comparative efficacy of glucose-lowering drugs on liver steatosis as assessed by means of magnetic resonance imaging in patients with type 2 diabetes mellitus: systematic review and network meta-analysis","volume":"22","author":"Malandris","year":"2023","journal-title":"Hormones (Athens)"},{"key":"10.1016\/j.jacc.2025.07.052_bib195","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/cvr\/cvx186","article-title":"Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability","volume":"114","author":"D\u00edaz-Rodr\u00edguez","year":"2018","journal-title":"Cardiovasc Res"},{"issue":"1","key":"10.1016\/j.jacc.2025.07.052_bib196","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00018-024-05558-9","article-title":"The protective effects of liraglutide in reducing lipid droplets accumulation and myocardial fibrosis in diabetic cardiomyopathy","volume":"82","author":"Kuo","year":"2025","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jacc.2025.07.052_bib197","first-page":"140","article-title":"The GLP-1 receptor agonist liraglutide increases myocardial glucose oxidation rates via indirect mechanisms and mitigates experimental diabetic cardiomyopathy","volume":"37","author":"Almutairi","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacc.2025.07.052_bib198","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.2337\/db16-0733","article-title":"The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model","volume":"66","author":"Joubert","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.jacc.2025.07.052_bib199","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1393946","article-title":"Empagliflozin alters lipid metabolism in the myocardium and liver in a prediabetes model with severe dyslipidemia","volume":"15","author":"Miklankova","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jacc.2025.07.052_bib200","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s10557-020-06989-9","article-title":"Empagliflozin protects cardiac mitochondrial fatty acid metabolism in a mouse model of diet-induced lipid overload","volume":"34","author":"Makrecka-Kuka","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacc.2025.07.052_bib201","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.113677","article-title":"Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats","volume":"170","author":"Arag\u00f3n-Herrera","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jacc.2025.07.052_bib202","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1161\/CIRCULATIONAHA.124.069479","article-title":"Effects of dapagliflozin on body composition and its relation to hemodynamics in heart failure with preserved ejection fraction","volume":"149","author":"Naser","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.07.052_bib203","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3748\/wjg.v23.i1.141","article-title":"Sitagliptin in patients with non-alcoholic steatohepatitis: a randomized, placebo-controlled trial","volume":"23","author":"Joy","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jacc.2025.07.052_bib204","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.metabol.2004.07.008","article-title":"Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial","volume":"54","author":"Smith","year":"2005","journal-title":"Metabolism"},{"key":"10.1016\/j.jacc.2025.07.052_bib205","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1210\/jc.2009-1441","article-title":"Pioglitazone compared with metformin increases pericardial fat volume in patients with type 2 diabetes mellitus","volume":"9","author":"Jonker","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.jacc.2025.07.052_bib206","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035999","article-title":"Effects of PPARs agonists on cardiac metabolism in littermate and cardiomyocyte-specific PPAR-gamma-knockout (CM-PGKO) mice","volume":"7","author":"Barbieri","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2025.07.052_bib207","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1096\/fasebj.13.13.1833","article-title":"Role of the sulfonylurea receptor in regulating human adipocyte metabolism","volume":"13","author":"Shi","year":"1999","journal-title":"FASEB J"},{"key":"10.1016\/j.jacc.2025.07.052_bib208","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3109\/13813455.2013.796996","article-title":"Pharmacologic agents for type 2 diabetes therapy and regulation of adipogenesis","volume":"119","author":"Cignarelli","year":"2013","journal-title":"Arch Physiol Biochem"},{"issue":"23","key":"10.1016\/j.jacc.2025.07.052_bib209","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.3390\/jcm10235516","article-title":"Impact of bariatric surgery on adipose tissue biology","volume":"10","author":"Osorio-Conles","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacc.2025.07.052_bib210","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","article-title":"New type of cardiomyopathy associated with diabetic glomerulosclerosis","volume":"30","author":"Rubler","year":"1972","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2025.07.052_bib211","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/eurheartj\/ehv134","article-title":"Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes","volume":"36","author":"Seferovi\u0107","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.07.052_bib212","first-page":"1893","article-title":"Diabetic myocardial disorder. A clinical consensus statement of the Heart Failure Association of the ESC and the ESC Working Group on Myocardial & Pericardial Diseases","volume":"26","author":"Seferovi\u0107","year":"2024","journal-title":"Eur J Heart Fail"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725073413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725073413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T01:24:17Z","timestamp":1766193857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109725073413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":212,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0735109725073413"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2025.07.052","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is Type 2 Diabetes a Modifiable Risk Factor for the Evolution and Progression of Heart Failure With a Preserved Ejection Fraction?","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.07.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}